These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 20112854)

  • 1. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.
    Mukherjee AK; Reddy VS; Shah S; Jhingan AK; Ramakrishnan P; Prusty V; Singh NS
    J Indian Med Assoc; 2009 Jul; 107(7):464-70. PubMed ID: 20112854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DIAB.&TE.S Project: how patients perceive diabetes and diabetes therapy.
    Marra G;
    Acta Biomed; 2004 Dec; 75(3):164-70. PubMed ID: 15796090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine.
    Bradley C; Gilbride CJ
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():50-65. PubMed ID: 18577157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes.
    Reimer T; Hohberg C; Pfützner AH; Jørgensen C; Jensen KH; Pfützner A
    Clin Ther; 2008 Dec; 30(12):2252-62. PubMed ID: 19167585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe.
    Stockl K; Ory C; Vanderplas A; Nicklasson L; Lyness W; Cobden D; Chang E
    Curr Med Res Opin; 2007 Jan; 23(1):133-46. PubMed ID: 17257475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patient satisfaction in diabetes mellitus--measures and results].
    Kohlmann T; Moock J
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S120-3; discussion S124-6. PubMed ID: 18686221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
    Clark PE; Valentine V; Bodie JN; Sarwat S
    Curr Med Res Opin; 2010 Jul; 26(7):1745-53. PubMed ID: 20482243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
    Yang W; Gao Y; Liu G; Chen L; Fu Z; Zou D; Feng P; Zhao Z
    Curr Med Res Opin; 2010 Jan; 26(1):101-7. PubMed ID: 19916705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
    Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
    Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice.
    Shah SN; Litwak L; Haddad J; Chakkarwar PN; Hajjaji I
    Diabetes Res Clin Pract; 2010 May; 88 Suppl 1():S11-6. PubMed ID: 20466163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin therapy and quality of life. A review.
    Pouwer F; Hermanns N
    Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S4-S10. PubMed ID: 19662621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.